Skip to main content
Home
Latest news
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH
Top

02-06-2018 | Osteoporosis | Review | Article

Efficacy of anti-osteoporotic medications in patients with type 1 and 2 diabetes mellitus: a systematic review

Journal: Endocrine

Authors: Panagiotis Anagnostis, Stavroula A. Paschou, Nifon N. Gkekas, Aikaterini-Maria Artzouchaltzi, Konstantinos Christou, Dimitrios Stogiannou, Andromachi Vryonidou, Michael Potoupnis, Dimitrios G. Goulis

Publisher: Springer US

Login to get access

Abstract

Purpose

Both type 1 (T1DM) and type 2 diabetes mellitus (T2DM) have been associated with bone fragility and increased fracture risk. However, little is known regarding the effect of anti-osteoporotic treatment on bone mineral density (BMD) and/or fracture risk in these patients. We aimed to systematically investigate the efficacy of anti-osteoporotic medications in patients with diabetes in comparison with non-diabetic subjects.

Methods

MEDLINE and Scopus databases were searched (up to 31st October 2017).

Results

Nine studies fulfilled the pre-defined inclusion criteria [patients with T2DM (n = 8) or either T1DM or T2DM (n = 1)]. Regarding fracture risk, five studies were identified. Alendronate demonstrated comparable vertebral anti-fracture efficacy in patients with and without diabetes (n = 2), whereas non-vertebral fracture risk was either the same (n = 1) or higher in diabetic patients (n = 1). Raloxifene also demonstrated comparable vertebral anti-fracture efficacy in both groups (n = 2), without any effect on non-vertebral fractures in either group. In one study, diabetic patients exposed to raloxifene demonstrated the same vertebral and non-vertebral fracture risk with non-diabetic patients. Teriparatide (n = 1) demonstrated the same non-vertebral fracture rates in both patients with and without T2DM. Regarding BMD, equal increases in spine BMD were observed with alendronate (n = 4), risedronate (n = 1), and teriparatide (n = 1). With respect to hip BMD, similar increases were observed with teriparatide (n = 1), whereas data regarding alendronate were controversial (n = 3). No eligible study was found for zoledronic acid, ibandronate, strontium ranelate, denosumab, or bazedoxifene.

Conclusions

The presence of diabetes does not alter anti-osteoporotic treatment response, regarding BMD increase and vertebral fracture risk reduction.
Literature
1.
R. Bouillon, Diabetic bone disease. Calcif. Tissue Int. 49, 155–160 (1991)CrossRefPubMed
2.
S.A. Paschou, P. Anagnostis, A. Vryonidou, D.G. Goulis, Editorial: Diabetes and atherosclerosis: old players in a new field, osteoporosis. Curr. Vasc. Pharmacol. (2017). https://​doi.​org/​10.​2174/​1570161116666171​205104851
3.
S. Epstein, D. Leroith, Diabetes and fragility fractures–a burgeoning epidemic? Bone 43, 3–6 (2008)CrossRefPubMed
4.
J.C. Krakauer, M.J. McKenna, N.F. Buderer, D.S. Rao, F.W. Whitehouse, A.M. Parfitt, Bone loss and bone turnover in diabetes. Diabetes 44, 775–782 (1995)CrossRefPubMed
5.
M. Janghorbani, R.M. Van Dam, W.C. Willett, F.B. Hu, Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am. J. Epidemiol. 166, 495–505 (2007)CrossRefPubMed
6.
P. Vestergaard, Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes-a meta-analysis. Osteoporos. Int. 18, 427–444 (2007)CrossRefPubMed
7.
J.A. Kanis, O. Johnell, A. Oden, H. Johansson, E. McCloskey, FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos. Int. 19, 385–397 (2008)CrossRefPubMedPubMedCentral
8.
C. Adil, T. Aydın, Ö. Taşpınar, et al., Bone mineral density evaluation of patients with type 2 diabetes mellitus. J. Phys. Ther. Sci. 27, 179–182 (2015).CrossRefPubMedPubMedCentral
9.
E.K. Caglayan, Y. Engin-Ustun, N. Sari, S. Karacavus, L. Seckin, M. Kara, Evaluation of bone density measurement in type 2 diabetic postmenopausal women with hypertension and hyperlipidemia. J. Menopausa. Med. 21, 36–40 (2015)CrossRef
10.
J.N. Farr, M.T. Drake, S. Amin, L.J. Melton 3rd, L.K. McCready, S. Khosla, In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J. Bone Miner. Res. 29, 787–795 (2014)CrossRefPubMedPubMedCentral
11.
V. Mpalaris, P. Anagnostis, D.G. Goulis, I. Iakovou, Complex association between body weight and fracture risk in postmenopausal women. Obes. Rev. 16, 225–233 (2015)CrossRefPubMed
12.
N. Napoli, M. Chandran, D.D. Pierroz, B. Abrahamsen, A.V. Schwartz, S.L. Ferrari; IOF Bone and Diabetes Working Group, Mechanisms of diabetes mellitus-induced bone fragility. Nat. Rev. Endocrinol. 13, 208–219 (2017)CrossRefPubMed
13.
S.A. Paschou, A.D. Dede, P. Anagnostis, A. Vryonidou, D. Morganstein, D.G. Goulis, Type 2 diabetes and osteoporosis: a guide to optimal management. J. Clin. Endocrinol. Metab. 102, 3621–3634 (2017).CrossRefPubMed
14.
A. Liberati, D.G. Altman, J. Tetzlaff et al., The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339, 2700 (2009)CrossRef
15.
A. Stang, Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol. 25, 603–605 (2010).CrossRefPubMed
16.
P. Vestergaard, L. Rejnmark, L. Mosekilde, Are antiresorptive drugs effective against fractures in patients with diabetes? Calcif. Tissue Int. 88, 209–214 (2011)CrossRefPubMed
17.
R. Nan, D. Grigorie, A. Cursaru et al., Bisphosphonates-a good choice for women with type 2 diabetes and postmenopausal osteoporosis? Farmacia 64, 2 (2016)
18.
T.H. Keegan, A.V. Schwartz, D.C. Bauer, D.E. Sellmeyer, J.L. Kelsey, Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial. Diabetes Care 27, 1547–1553 (2004)CrossRefPubMed
19.
J. Iwamoto, Y. Sato, M. Uzawa, T. Takeda, H. Matsumoto, Three-year experience with alendronate treatment in postmenopausal osteoporotic Japanese women with or without type 2 diabetes. Diabetes Res. Clin. Pract. 93, 166–173 (2011)CrossRefPubMed
20.
S. Dagdelen, D. Sener, M. Bayraktar, Influence of type 2 diabetes mellitus on bone mineral density response to bisphosphonates in late postmenopausal osteoporosis. Adv. Ther. 24, 1314–1320 (2007)CrossRefPubMed
21.
D. Inoue, R. Muraoka, R. Okazaki, Y. Nishizawa, T. Sugimoto, Efficacy and safety of risedronate in osteoporosis subjectswith comorbid diabetes, hypertension, and/or dyslipidemia: a post hoc analysis of phase III trials conducted in Japan. Calcif. Tissue Int. 98, 114–122 (2016)CrossRefPubMed
22.
O. Johnell, J.A. Kanis, D.M. Black et al., Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. J. Bone Miner. Res. 19, 764–772 (2004)CrossRefPubMed
23.
K.E. Ensrud, J.L. Stock, E. Barrett-Connor et al., Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial. J. Bone Miner. Res. 23, 112–120 (2008)CrossRefPubMed
24.
A.V. Schwartz, I. Pavo, J. Alam et al., Teriparatide in patients with osteoporosis and type 2 diabetes. Bone 91, 152–158 (2016)CrossRefPubMed
25.
A. Moayeri, M. Mohamadpour, S.F. Mousavi, E. Shirzadpour, S. Mohamadpour, M. Amraei, Fracture risk in patients with type 2 diabetes mellitus and possible risk factors: a systematic review and meta-analysis. Ther. Clin. Risk. Manag. 13, 455–468 (2017)CrossRefPubMedPubMedCentral
26.
J. Dytfeld, M. Michalak, Type 2 diabetes and risk of low-energy fractures in postmenopausal women: meta-analysis of observational studies. Aging Clin. Exp. Res. 29, 301–309 (2017)CrossRefPubMed
27.
Y. Fan, F. Wei, Y. Lang, Y. Liu, Diabetes mellitus and risk of hip fractures: a meta-analysis. Osteoporos. Int. 27, 219–228 (2016)CrossRefPubMed
28.
E.A. De Waard, T.A. Van Geel, H.H. Savelberg, A. Koster, P.P. Geusens, J.P. van den Bergh, Increased fracture risk in patients with type 2 diabetes mellitus: an overview of the underlying mechanisms and the usefulness of imaging modalities and fracture risk assessment tools. Maturitas 79, 265–274 (2014)CrossRefPubMed
29.
L. Ma, L. Oei, L. Jiang et al., Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies. Eur. J. Epidemiol. 27, 319–332 (2012)CrossRefPubMedPubMedCentral
30.
G.I. Schacter, W.D. Leslie, DXA-based measurements in diabetes: can they predict fracture risk? Calcif. Tissue Int. 100, 150–164 (2017)CrossRefPubMed
31.
L.M. Giangregorio, W.D. Leslie, L.M. Lix, H. Johansson, A. Oden, E. McCloskey, J.A. Kanis, FRAX underestimates fracture risk in patients with diabetes. J. Bone Miner. Res. 27, 301–8 (2012)CrossRefPubMed
32.
A.V. Schwartz, E. Vittinghoff, D.C. Bauer, T.A. Hillier, E.S. Strotmeyer, K.E. Ensrud, M.G. Donaldson, J.A. Cauley, T.B. Harris, A. Koster, C.R. Womack, L. Palermo, D.M. Black, Study of Osteoporotic Fractures (SOF) Research Group; Osteoporotic Fractures in Men (MrOS) Research Group; Health, Aging, and Body Composition (Health ABC) Research Group. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA 305(21), 2184–92 (2011)CrossRefPubMedPubMedCentral
33.
J.H. Kim, H.J. Choi, E.J. Ku et al., Trabecular bone score as an indicator for skeletal deterioration in diabetes. J. Clin. Endocrinol. Metab. 100, 475–482 (2015)CrossRefPubMed
34.
W.D. Leslie, B. Aubry-Rozier, O. Lamy, D. Hans, Manitoba bone density program. TBS (trabecular bone score) and diabetes-related fracture risk. J. Clin. Endocrinol. Metab. 98(2), 602–9 (2013)CrossRefPubMed
35.
A.J. Burghardt, A.S. Issever, A.V. Schwartz et al., High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 95, 5045–5055 (2010)CrossRefPubMedPubMedCentral
36.
A.G. Nilsson, D. Sundh, L. Johansson et al., Type 2 diabetes mellitus is associated with better bone microarchitecture but lower bone material Strength and poorer physical function in elderly women: a population-based Study. J. Bone Miner. Res. 32, 1062–1071 (2017)CrossRefPubMed
37.
J. Starup-Linde, S.A. Eriksen, S. Lykkeboe, A. Handberg, P. Vestergaard, Biochemical markers of bone turnover in diabetes patients-a meta-analysis, and a methodological study on the effects of glucose on bone markers. Osteoporos 25, 1697–1708 (2014)CrossRef
38.
J. Starup-Linde, Diabetes, biochemical markers of bone turnover, diabetes control, and bone. Front. Endocrinol. 4, 21 (2013)CrossRef
39.
V.N.Shah, K.K.Harrall, C.S.Shah, et al., Bone mineral density at femoral neck and lumbar spine in adults with type 1 diabetes: a meta-analysis and review of the literature. Osteoporos. Int 28, 2601–2610 (2017).CrossRefPubMed
40.
J. Starup-Linde, S. Lykkeboe, S. Gregersen et al., Bone structure and predictors of fracture in type 1 and type 2 diabetes. J. Clin. Endocrinol. Metab. 101, 928–936 (2016)CrossRefPubMed
41.
C. Verroken, W. Pieters, L. Beddeleem et al., Cortical bone size deficit in adult patients with type 1 diabetes mellitus. J. Clin. Endocrinol. Metab. 102, 2887–2895 (2017)CrossRefPubMed
42.
M.M. Campos Pastor, J.D. Luna, F. Escobar-Jimenez, F.J. Gomez Jimenez, M.D. Serrano Pardo, P. Lopez-Ibarra, Effects of risedronate on metabolic bone disease in patients with type 1 diabetes and osteoporosis. Rev. Esp. Enferm. Metab. Oseas. 17, 66–70 (2008)
43.
R.E. Aubert, V. Herrera, W. Chen, S.M. Haffner, M. Pendergrass, Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes. Diabetes Obes. Metab. 12, 716–721 (2010)CrossRefPubMed

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »

Image Credits